Furiex Pharmaceuticals Inc. (FURX): Magnetar Capital Reveals 10% Stake; Garnero Group Acquisition Co. (GGACU): Glazer Capital Reports 6% Stake

In a new filing with the U.S. Securities and Exchange Commission, Magnetar Capital, run by Alec Litowitz and Ross Laser, has disclosed a new position in Furiex Pharmaceuticals Inc. (NASDAQ:FURX). According to the filing, Magnetar Capital owns 1.08 million shares of the company, representing 9.98% of common stock.

Furiex Pharmaceuticals Inc (FURX)

With a market cap of $1.13 billion, Furiex Pharmaceuticals Inc. (NASDAQ:FURX) is a drug development collaboration company. The company was acquired by Forest Laboratories, a subsidiary of Actavis plc (NYSE: ACT), in an all-cash transaction valued at about $1.1 billion, and up to about $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval, according to a news release.

The largest shareholders of the company include Mitchell Blutt’s Consonance Capital Management, which owns 616,495 shares, and Casey Nelson’s Alistair Capital, which holds 84,938 shares. Another investor, Neil Shah’s March Altus Capital Management disclosed ownership of 69,960 shares of Furiex Pharmaceuticals Inc. (NASDAQ:FURX).

In another filing, Glazer Capital, managed by Paul Glazer, has disclosed a new position in Garnero Group Acquisition Co. (NASDAQ:GGACU). In a new filing with the SEC, Glazer Capital has revealed that it holds 1.10 million ordinary shares of the company, The stake equates to 6.8% of class, and is passive by nature.

Garnero Group Acquisition Co. (NASDAQ:GGACU) is a newly formed blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition or other similar business combination with one or more businesses or entities. Garnero Group Acquisition Co. (NASDAQ:GGACU) recently conducted its initial public offering of 12.50 million units. The underwriters of the offering have exercised their over-allotment option in full and that the closing of the sale of the 1.88 million units has taken place.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!